VC Fund Investments
Cell therapy player Eyestem raises $6.4 M from strategic investors, existing VCs
Eyestem, a Bengaluru-based cell therapy company, has raised USD 6.4 million (INR 51 crore) in a Series A round led by Biological E, Alkem, Natco and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing PE-VC investors Endiya Partners and Kotak Private Equity also participated in this round, which valued Eyestem at USD 46.4 million (INR 371 crore). Eyecyte-RPE, the company's patented flagship product, is an experimental treatment for Dry Age-Related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases.
From the Venture Intelligence PE-VC Deal Database: In May-2021, Eyestem had raised over INR 5 Cr from Endiya Partners and Kotak Investment Advisors. (Subscribers to the database can login to view the valuation, deal structuring and other transaction details.)
Want to receive such news items in your inbox? Click Here to sign up for a trial.
